Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032

Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Pharma & Healthcare

Published Date: 2026-04-16

Pages: 164 Pages

Report ld: 6456594

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Omalizumab Biosimilars Market Size(US$)

CAGR 2026-2032

11.2%

Market Size,2032

USD 598

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 315 million

Market Forecast in 2032(Value)

US$ 598 million

CAGR

11.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

In 2025, global Omalizumab Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

The market is entering a rapid commercialization stage

As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.

Price competition will become increasingly important

As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.

Interchangeability will become a key competitive advantage

In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.

More dosage forms and specifications will be introduced

Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.

Expansion of indications will increase long-term market potential

As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.

Report Includes:

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Omalizumab Biosimilars market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

MARKET SEGMENTATION

By Company

Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

150 mg/mL
75 mg/0.5 mL

Segment by Application

Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria

Segment by Category

For Adults
For Teenagers
For Children

Segment by Division

Every 2 Weeks
Every 4 Weeks
Individualized Dosing Regimen

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Omalizumab Biosimilars study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application

Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles

Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments

Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Omalizumab Biosimilars: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Omalizumab Biosimilars Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 150 mg/mL

1.2.3 75 mg/0.5 mL

1.3 Market Segmentation by Age

1.3.1 Global Omalizumab Biosimilars Market Size by Age, 2021 vs 2025 vs 2032

1.3.2 For Adults

1.3.3 For Teenagers

1.3.4 For Children

1.4 Market Segmentation by Frequency

1.4.1 Global Omalizumab Biosimilars Market Size by Frequency, 2021 vs 2025 vs 2032

1.4.2 Every 2 Weeks

1.4.3 Every 4 Weeks

1.4.4 Individualized Dosing Regimen

1.5 Market Segmentation by Application

1.5.1 Global Omalizumab Biosimilars Market Size by Application, 2021 vs 2025 vs 2032

1.5.2 Persistent Asthma

1.5.3 Nasal Polyps

1.5.4 Chronic Idiopathic Urticaria

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Executive Summary

2.1 Global Omalizumab Biosimilars Revenue Estimates and Forecasts (2021-2032)

2.2 Global Omalizumab Biosimilars Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.3 Global Omalizumab Biosimilars Sales Estimates and Forecasts (2021-2032)

2.4 Global Omalizumab Biosimilars Sales by Region

2.4.1 Sales Comparison: 2021 vs 2025 vs 2032

2.4.2 Historical and Forecasted Sales by Region (2021-2032)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape

3.1 Global Omalizumab Biosimilars Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2021-2026)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)

3.2 Global Omalizumab Biosimilars Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)

3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)

3.3.2 Manufacturer-Level Price Trends (2021-2026)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Key Manufacturers Market Share by Product Type

3.5.1 150 mg/mL: Market Share by Key Manufacturers

3.5.2 75 mg/0.5 mL: Market Share by Key Manufacturers

3.6 Global Omalizumab Biosimilars Market Concentration and Dynamics

3.6.1 Global Market Concentration

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation

4.1 Global Omalizumab Biosimilars Sales Performance by Type

4.1.1 Global Omalizumab Biosimilars Sales Volume by Type (2021-2032)

4.1.2 Global Omalizumab Biosimilars Revenue by Type (2021-2032)

4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)

4.2 Global Omalizumab Biosimilars Sales Performance by Age

4.2.1 Global Omalizumab Biosimilars Sales Volume by Age (2021-2032)

4.2.2 Global Omalizumab Biosimilars Revenue by Age (2021-2032)

4.2.3 Global Average Selling Price (ASP) Trends by Age (2021-2032)

4.3 Global Omalizumab Biosimilars Sales Performance by Frequency

4.3.1 Global Omalizumab Biosimilars Sales Volume by Frequency (2021-2032)

4.3.2 Global Omalizumab Biosimilars Revenue by Frequency (2021-2032)

4.3.3 Global Average Selling Price (ASP) Trends by Frequency (2021-2032)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global Omalizumab Biosimilars Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)

5.1.2 Global Sales Market Share by Application (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Omalizumab Biosimilars Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)

5.2.2 Revenue-Based Market Share by Application (2021-2032)

5.3 Global Pricing Dynamics by Application (2021-2032)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2021-2032)

6.2 North America Key Manufacturers Sales Revenue in 2025

6.3 North America Omalizumab Biosimilars Sales and Revenue by Application (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America Omalizumab Biosimilars Market Size by Country

6.5.1 North America Revenue by Country

6.5.2 North America Sales Trends by Country

6.5.3 US

6.5.4 Canada

6.5.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2021-2032)

7.2 Europe Key Manufacturers Sales Revenue in 2025

7.3 Europe Omalizumab Biosimilars Sales and Revenue by Application (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe Omalizumab Biosimilars Market Size by Country

7.5.1 Europe Revenue by Country

7.5.2 Europe Sales Trends by Country

7.5.3 Germany

7.5.4 France

7.5.5 U.K.

7.5.6 Italy

7.5.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025

8.3 Asia-Pacific Omalizumab Biosimilars Sales and Revenue by Application (2021-2032)

8.4 Asia-Pacific Omalizumab Biosimilars Market Size by Region

8.4.1 Asia-Pacific Revenue by Region

8.4.2 Asia-Pacific Sales Trends by Region

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Southeast Asia

8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)

8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.7 China

8.8 Japan

8.9 South Korea

8.10 China Taiwan

8.11 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2021-2032)

9.2 Central and South America Key Manufacturers Sales Revenue in 2025

9.3 Central and South America Omalizumab Biosimilars Sales and Revenue by Application (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America Omalizumab Biosimilars Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025

10.3 Middle East and Africa Omalizumab Biosimilars Sales and Revenue by Application (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa Omalizumab Biosimilars Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Turkey

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 Roche

11.1.1 Roche Corporation Information

11.1.2 Roche Business Overview

11.1.3 Roche Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.1.4 Roche Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.1.5 Roche Omalizumab Biosimilars Sales by Product in 2025

11.1.6 Roche Omalizumab Biosimilars Sales by Application in 2025

11.1.7 Roche Omalizumab Biosimilars Sales by Geographic Area in 2025

11.1.8 Roche Omalizumab Biosimilars SWOT Analysis

11.1.9 Roche Recent Developments

11.2 Novartis

11.2.1 Novartis Corporation Information

11.2.2 Novartis Business Overview

11.2.3 Novartis Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.2.4 Novartis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.2.5 Novartis Omalizumab Biosimilars Sales by Product in 2025

11.2.6 Novartis Omalizumab Biosimilars Sales by Application in 2025

11.2.7 Novartis Omalizumab Biosimilars Sales by Geographic Area in 2025

11.2.8 Novartis Omalizumab Biosimilars SWOT Analysis

11.2.9 Novartis Recent Developments

11.3 Glenmark Pharmaceuticals

11.3.1 Glenmark Pharmaceuticals Corporation Information

11.3.2 Glenmark Pharmaceuticals Business Overview

11.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.3.5 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales by Product in 2025

11.3.6 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales by Application in 2025

11.3.7 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales by Geographic Area in 2025

11.3.8 Glenmark Pharmaceuticals Omalizumab Biosimilars SWOT Analysis

11.3.9 Glenmark Pharmaceuticals Recent Developments

11.4 Selexis

11.4.1 Selexis Corporation Information

11.4.2 Selexis Business Overview

11.4.3 Selexis Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.4.4 Selexis Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.4.5 Selexis Omalizumab Biosimilars Sales by Product in 2025

11.4.6 Selexis Omalizumab Biosimilars Sales by Application in 2025

11.4.7 Selexis Omalizumab Biosimilars Sales by Geographic Area in 2025

11.4.8 Selexis Omalizumab Biosimilars SWOT Analysis

11.4.9 Selexis Recent Developments

11.5 Generium

11.5.1 Generium Corporation Information

11.5.2 Generium Business Overview

11.5.3 Generium Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.5.4 Generium Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.5.5 Generium Omalizumab Biosimilars Sales by Product in 2025

11.5.6 Generium Omalizumab Biosimilars Sales by Application in 2025

11.5.7 Generium Omalizumab Biosimilars Sales by Geographic Area in 2025

11.5.8 Generium Omalizumab Biosimilars SWOT Analysis

11.5.9 Generium Recent Developments

11.6 CuraTeQ

11.6.1 CuraTeQ Corporation Information

11.6.2 CuraTeQ Business Overview

11.6.3 CuraTeQ Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.6.4 CuraTeQ Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.6.5 CuraTeQ Recent Developments

11.7 Celltrion Healthcare

11.7.1 Celltrion Healthcare Corporation Information

11.7.2 Celltrion Healthcare Business Overview

11.7.3 Celltrion Healthcare Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.7.4 Celltrion Healthcare Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.7.5 Celltrion Healthcare Recent Developments

11.8 Alvotech

11.8.1 Alvotech Corporation Information

11.8.2 Alvotech Business Overview

11.8.3 Alvotech Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.8.4 Alvotech Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.8.5 Alvotech Recent Developments

11.9 BiosanaPharma

11.9.1 BiosanaPharma Corporation Information

11.9.2 BiosanaPharma Business Overview

11.9.3 BiosanaPharma Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.9.4 BiosanaPharma Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.9.5 BiosanaPharma Recent Developments

11.10 Mabpharm

11.10.1 Mabpharm Corporation Information

11.10.2 Mabpharm Business Overview

11.10.3 Mabpharm Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.10.4 Mabpharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.10.5 Mabpharm Recent Developments

11.11 CSPC Pharmaceutical Group

11.11.1 CSPC Pharmaceutical Group Corporation Information

11.11.2 CSPC Pharmaceutical Group Business Overview

11.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.11.5 CSPC Pharmaceutical Group Recent Developments

11.12 Biomabs

11.12.1 Biomabs Corporation Information

11.12.2 Biomabs Business Overview

11.12.3 Biomabs Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.12.4 Biomabs Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.12.5 Biomabs Recent Developments

11.13 HisunPharm

11.13.1 HisunPharm Corporation Information

11.13.2 HisunPharm Business Overview

11.13.3 HisunPharm Omalizumab Biosimilars Product Models, Descriptions and Specifications

11.13.4 HisunPharm Omalizumab Biosimilars Sales, Price, Revenue and Gross Margin (2021-2026)

11.13.5 HisunPharm Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Omalizumab Biosimilars Industry Chain

12.2 Omalizumab Biosimilars Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Omalizumab Biosimilars Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2021-2032)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Omalizumab Biosimilars Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Omalizumab Biosimilars Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Omalizumab Biosimilars Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global Omalizumab Biosimilars Market Size Growth Rate by Age, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global Omalizumab Biosimilars Market Size Growth Rate by Frequency, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 6. Global Omalizumab Biosimilars Revenue by Region (US$ Million), 2021-2026

Table 7. Global Omalizumab Biosimilars Revenue by Region (US$ Million), 2027-2032

Table 8. Global Omalizumab Biosimilars Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)

Table 9. Global Omalizumab Biosimilars Sales by Region (K Dose), 2021-2026

Table 10. Global Omalizumab Biosimilars Sales by Region (K Dose), 2027-2032

Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 12. Global Omalizumab Biosimilars Sales by Manufacturers (K Dose), 2021-2026

Table 13. Global Omalizumab Biosimilars Sales Share by Manufacturers (2021-2026)

Table 14. Global Omalizumab Biosimilars Revenue by Manufacturers (US$ Million), 2021-2026

Table 15. Global Omalizumab Biosimilars Revenue-Based Market Share by Manufacturers (2021-2026)

Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)

Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Omalizumab Biosimilars Revenue, 2025

Table 18. Global Omalizumab Biosimilars Average Gross Margin (%) by Manufacturer (2021 vs 2025)

Table 19. Global Omalizumab Biosimilars Average Selling Price (ASP) by Manufacturers (US$/Dose), 2021-2026

Table 20. Key Manufacturers Omalizumab Biosimilars Manufacturing Base and Headquarters

Table 21. Global Omalizumab Biosimilars Market Concentration Ratio (CR5)

Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 24. Global Omalizumab Biosimilars Sales Volume by Type (K Dose), 2021-2026

Table 25. Global Omalizumab Biosimilars Sales Volume by Type (K Dose), 2027-2032

Table 26. Global Omalizumab Biosimilars Revenue by Type (US$ Million), 2021-2026

Table 27. Global Omalizumab Biosimilars Revenue by Type (US$ Million), 2027-2032

Table 28. Global Omalizumab Biosimilars Sales Volume by Age (K Dose), 2021-2026

Table 29. Global Omalizumab Biosimilars Sales Volume by Age (K Dose), 2027-2032

Table 30. Global Omalizumab Biosimilars Revenue by Age (US$ Million), 2021-2026

Table 31. Global Omalizumab Biosimilars Revenue by Age (US$ Million), 2027-2032

Table 32. Global Omalizumab Biosimilars Sales Volume by Frequency (K Dose), 2021-2026

Table 33. Global Omalizumab Biosimilars Sales Volume by Frequency (K Dose), 2027-2032

Table 34. Global Omalizumab Biosimilars Revenue by Frequency (US$ Million), 2021-2026

Table 35. Global Omalizumab Biosimilars Revenue by Frequency (US$ Million), 2027-2032

Table 36. Technical Specifications by Key Product Type

Table 37. Global Omalizumab Biosimilars Sales by Application (K Dose), 2021-2026

Table 38. Global Omalizumab Biosimilars Sales by Application (K Dose), 2027-2032

Table 39. Omalizumab Biosimilars High-Growth Sectors Demand CAGR (2026-2032)

Table 40. Global Omalizumab Biosimilars Revenue by Application (US$ Million), 2021-2026

Table 41. Global Omalizumab Biosimilars Revenue by Application (US$ Million), 2027-2032

Table 42. Top Customers by Region

Table 43. Top Customers by Application

Table 44. North America Omalizumab Biosimilars Growth Accelerators and Market Barriers

Table 45. North America Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 46. North America Omalizumab Biosimilars Sales (K Dose) by Country (2021 vs 2025 vs 2032)

Table 47. Europe Omalizumab Biosimilars Growth Accelerators and Market Barriers

Table 48. Europe Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 49. Europe Omalizumab Biosimilars Sales (K Dose) by Country (2021 vs 2025 vs 2032)

Table 50. Asia-Pacific Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 51. Asia-Pacific Omalizumab Biosimilars Sales (K Dose) by Country (2021 vs 2025 vs 2032)

Table 52. Asia-Pacific Omalizumab Biosimilars Growth Accelerators and Market Barriers

Table 53. Southeast Asia Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 54. Central and South America Omalizumab Biosimilars Investment Opportunities and Key Challenges

Table 55. Central and South America Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 56. Middle East and Africa Omalizumab Biosimilars Investment Opportunities and Key Challenges

Table 57. Middle East and Africa Omalizumab Biosimilars Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 58. Roche Corporation Information

Table 59. Roche Description and Major Businesses

Table 60. Roche Product Models, Descriptions and Specifications

Table 61. Roche Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 62. Roche Sales Value Proportion by Product in 2025

Table 63. Roche Sales Value Proportion by Application in 2025

Table 64. Roche Sales Value Proportion by Geographic Area in 2025

Table 65. Roche Omalizumab Biosimilars SWOT Analysis

Table 66. Roche Recent Developments

Table 67. Novartis Corporation Information

Table 68. Novartis Description and Major Businesses

Table 69. Novartis Product Models, Descriptions and Specifications

Table 70. Novartis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 71. Novartis Sales Value Proportion by Product in 2025

Table 72. Novartis Sales Value Proportion by Application in 2025

Table 73. Novartis Sales Value Proportion by Geographic Area in 2025

Table 74. Novartis Omalizumab Biosimilars SWOT Analysis

Table 75. Novartis Recent Developments

Table 76. Glenmark Pharmaceuticals Corporation Information

Table 77. Glenmark Pharmaceuticals Description and Major Businesses

Table 78. Glenmark Pharmaceuticals Product Models, Descriptions and Specifications

Table 79. Glenmark Pharmaceuticals Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 80. Glenmark Pharmaceuticals Sales Value Proportion by Product in 2025

Table 81. Glenmark Pharmaceuticals Sales Value Proportion by Application in 2025

Table 82. Glenmark Pharmaceuticals Sales Value Proportion by Geographic Area in 2025

Table 83. Glenmark Pharmaceuticals Omalizumab Biosimilars SWOT Analysis

Table 84. Glenmark Pharmaceuticals Recent Developments

Table 85. Selexis Corporation Information

Table 86. Selexis Description and Major Businesses

Table 87. Selexis Product Models, Descriptions and Specifications

Table 88. Selexis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 89. Selexis Sales Value Proportion by Product in 2025

Table 90. Selexis Sales Value Proportion by Application in 2025

Table 91. Selexis Sales Value Proportion by Geographic Area in 2025

Table 92. Selexis Omalizumab Biosimilars SWOT Analysis

Table 93. Selexis Recent Developments

Table 94. Generium Corporation Information

Table 95. Generium Description and Major Businesses

Table 96. Generium Product Models, Descriptions and Specifications

Table 97. Generium Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 98. Generium Sales Value Proportion by Product in 2025

Table 99. Generium Sales Value Proportion by Application in 2025

Table 100. Generium Sales Value Proportion by Geographic Area in 2025

Table 101. Generium Omalizumab Biosimilars SWOT Analysis

Table 102. Generium Recent Developments

Table 103. CuraTeQ Corporation Information

Table 104. CuraTeQ Description and Major Businesses

Table 105. CuraTeQ Product Models, Descriptions and Specifications

Table 106. CuraTeQ Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 107. CuraTeQ Recent Developments

Table 108. Celltrion Healthcare Corporation Information

Table 109. Celltrion Healthcare Description and Major Businesses

Table 110. Celltrion Healthcare Product Models, Descriptions and Specifications

Table 111. Celltrion Healthcare Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 112. Celltrion Healthcare Recent Developments

Table 113. Alvotech Corporation Information

Table 114. Alvotech Description and Major Businesses

Table 115. Alvotech Product Models, Descriptions and Specifications

Table 116. Alvotech Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 117. Alvotech Recent Developments

Table 118. BiosanaPharma Corporation Information

Table 119. BiosanaPharma Description and Major Businesses

Table 120. BiosanaPharma Product Models, Descriptions and Specifications

Table 121. BiosanaPharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 122. BiosanaPharma Recent Developments

Table 123. Mabpharm Corporation Information

Table 124. Mabpharm Description and Major Businesses

Table 125. Mabpharm Product Models, Descriptions and Specifications

Table 126. Mabpharm Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 127. Mabpharm Recent Developments

Table 128. CSPC Pharmaceutical Group Corporation Information

Table 129. CSPC Pharmaceutical Group Description and Major Businesses

Table 130. CSPC Pharmaceutical Group Product Models, Descriptions and Specifications

Table 131. CSPC Pharmaceutical Group Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 132. CSPC Pharmaceutical Group Recent Developments

Table 133. Biomabs Corporation Information

Table 134. Biomabs Description and Major Businesses

Table 135. Biomabs Product Models, Descriptions and Specifications

Table 136. Biomabs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 137. Biomabs Recent Developments

Table 138. HisunPharm Corporation Information

Table 139. HisunPharm Description and Major Businesses

Table 140. HisunPharm Product Models, Descriptions and Specifications

Table 141. HisunPharm Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)

Table 142. HisunPharm Recent Developments

Table 143. Key Raw Materials Distribution

Table 144. Raw Materials Key Suppliers

Table 145. Critical Raw Material Supplier Concentration (2025) & Risk Index

Table 146. Milestones in Production Technology Evolution

Table 147. Distributors List

Table 148. Market Trends and Market Evolution

Table 149. Market Drivers and Opportunities

Table 150. Market Challenges, Risks, and Restraints

Table 151. Research Programs/Design for This Report

Table 152. Key Data Information from Secondary Sources

Table 153. Key Data Information from Primary Sources

List of Figures

Figure 1. Omalizumab Biosimilars Product Picture

Figure 2. Global Omalizumab Biosimilars Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. 150 mg/mL Product Picture

Figure 4. 75 mg/0.5 mL Product Picture

Figure 5. Global Omalizumab Biosimilars Market Size Growth Rate by Age, 2021 vs 2025 vs 2032 (US$ Million)

Figure 6. For Adults Product Picture

Figure 7. For Teenagers Product Picture

Figure 8. For Children Product Picture

Figure 9. Global Omalizumab Biosimilars Market Size Growth Rate by Frequency, 2021 vs 2025 vs 2032 (US$ Million)

Figure 10. Every 2 Weeks Product Picture

Figure 11. Every 4 Weeks Product Picture

Figure 12. Individualized Dosing Regimen Product Picture

Figure 13. Global Omalizumab Biosimilars Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)

Figure 14. Persistent Asthma

Figure 15. Nasal Polyps

Figure 16. Chronic Idiopathic Urticaria

Figure 17. Omalizumab Biosimilars Report Years Considered

Figure 18. Global Omalizumab Biosimilars Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 19. Global Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 20. Global Omalizumab Biosimilars Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 21. Global Omalizumab Biosimilars Revenue-Based Market Share by Region (2021-2032)

Figure 22. Global Omalizumab Biosimilars Sales (K Dose), 2021-2032

Figure 23. Global Omalizumab Biosimilars Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)

Figure 24. Global Omalizumab Biosimilars Sales Market Share by Region (2021-2032)

Figure 25. Top 5 and Top 10 Manufacturers Omalizumab Biosimilars Sales Volume Market Share in 2025

Figure 26. Global Omalizumab Biosimilars Revenue-Based Market Share Ranking (2025)

Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 28. 150 mg/mL Revenue-Based Market Share by Manufacturer in 2025

Figure 29. 75 mg/0.5 mL Revenue-Based Market Share by Manufacturer in 2025

Figure 30. Global Omalizumab Biosimilars Sales Volume-Based Market Share by Type (2021-2032)

Figure 31. Global Omalizumab Biosimilars Revenue-Based Market Share by Type (2021-2032)

Figure 32. Global Omalizumab Biosimilars ASP by Type (US$/Dose), 2021-2032

Figure 33. Global Omalizumab Biosimilars Sales Volume-Based Market Share by Age (2021-2032)

Figure 34. Global Omalizumab Biosimilars Revenue-Based Market Share by Age (2021-2032)

Figure 35. Global Omalizumab Biosimilars ASP by Age (US$/Dose), 2021-2032

Figure 36. Global Omalizumab Biosimilars Sales Volume-Based Market Share by Frequency (2021-2032)

Figure 37. Global Omalizumab Biosimilars Revenue-Based Market Share by Frequency (2021-2032)

Figure 38. Global Omalizumab Biosimilars ASP by Frequency (US$/Dose), 2021-2032

Figure 39. Global Omalizumab Biosimilars Sales Market Share by Application (2021-2032)

Figure 40. Global Omalizumab Biosimilars Revenue-Based Market Share by Application (2021-2032)

Figure 41. Global Omalizumab Biosimilars ASP by Application (US$/Dose), 2021-2032

Figure 42. North America Omalizumab Biosimilars Sales YoY (K Dose), 2021-2032

Figure 43. North America Omalizumab Biosimilars Revenue YoY (US$ Million), 2021-2032

Figure 44. North America Top 5 Manufacturers Omalizumab Biosimilars Sales Revenue (US$ Million) in 2025

Figure 45. North America Omalizumab Biosimilars Sales Volume (K Dose) by Application (2021-2032)

Figure 46. North America Omalizumab Biosimilars Sales Revenue (US$ Million) by Application (2021-2032)

Figure 47. US Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 48. Canada Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 49. Mexico Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 50. Europe Omalizumab Biosimilars Sales YoY (K Dose), 2021-2032

Figure 51. Europe Omalizumab Biosimilars Revenue YoY (US$ Million), 2021-2032

Figure 52. Europe Top 5 Manufacturers Omalizumab Biosimilars Sales Revenue (US$ Million) in 2025

Figure 53. Europe Omalizumab Biosimilars Sales Volume (K Dose) by Application (2021-2032)

Figure 54. Europe Omalizumab Biosimilars Sales Revenue (US$ Million) by Application (2021-2032)

Figure 55. Germany Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 56. France Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 57. U.K. Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 58. Italy Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 59. Russia Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 60. Asia-Pacific Omalizumab Biosimilars Sales YoY (K Dose), 2021-2032

Figure 61. Asia-Pacific Omalizumab Biosimilars Revenue YoY (US$ Million), 2021-2032

Figure 62. Asia-Pacific Top 8 Manufacturers Omalizumab Biosimilars Sales Revenue (US$ Million) in 2025

Figure 63. Asia-Pacific Omalizumab Biosimilars Sales Volume (K Dose) by Application (2021-2032)

Figure 64. Asia-Pacific Omalizumab Biosimilars Sales Revenue (US$ Million) by Application (2021-2032)

Figure 65. Indonesia Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 66. Japan Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 67. South Korea Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 68. China Taiwan Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 69. India Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 70. Central and South America Omalizumab Biosimilars Sales YoY (K Dose), 2021-2032

Figure 71. Central and South America Omalizumab Biosimilars Revenue YoY (US$ Million), 2021-2032

Figure 72. Central and South America Top 5 Manufacturers Omalizumab Biosimilars Sales Revenue (US$ Million) in 2025

Figure 73. Central and South America Omalizumab Biosimilars Sales Volume (K Dose) by Application (2021-2032)

Figure 74. Central and South America Omalizumab Biosimilars Sales Revenue (US$ Million) by Application (2021-2032)

Figure 75. Brazil Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 76. Argentina Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 77. Middle East, and Africa Omalizumab Biosimilars Sales YoY (K Dose), 2021-2032

Figure 78. Middle East and Africa Omalizumab Biosimilars Revenue YoY (US$ Million), 2021-2032

Figure 79. Middle East and Africa Top 5 Manufacturers Omalizumab Biosimilars Sales Revenue (US$ Million) in 2025

Figure 80. Middle East and Africa Omalizumab Biosimilars Sales Volume (K Dose) by Application (2021-2032)

Figure 81. Middle East and Africa Omalizumab Biosimilars Sales Revenue (US$ Million) by Application (2021-2032)

Figure 82. GCC Countries Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 83. Turkey Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 84. Egypt Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 85. South Africa Omalizumab Biosimilars Revenue (US$ Million), 2021-2032

Figure 86. Omalizumab Biosimilars Industry Chain Mapping

Figure 87. Regional Omalizumab Biosimilars Manufacturing Base Distribution (%)

Figure 88. Global Omalizumab Biosimilars Production Market Share by Region (2021-2032)

Figure 89. Omalizumab Biosimilars Production Process

Figure 90. Regional Omalizumab Biosimilars Production Cost Structure

Figure 91. Channels of Distribution (Direct Vs Distribution)

Figure 92. Bottom-up and Top-down Approaches for This Report

Figure 93. Data Triangulation

Figure 94. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Omalizumab Biosimilars market? zhanKai

The top companies in the global Omalizumab Biosimilars market are Roche、Novartis、Glenmark Pharmaceuticals.

Which region is expected to have the highest market share? shouQi

What was the global market size of Omalizumab Biosimilars in 2032? shouQi

What is the annual compound growth rate of the global Omalizumab Biosimilars market size from 2026 to 2032? shouQi

What was the global market size of Omalizumab Biosimilars in 2026? shouQi

Related Reports

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 139
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published Date: 2026-04-16
Pages: 142
USD 4250.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 120
USD 2900.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 90
USD 2900.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-11
Pages: 122
USD 3950.00
(Single User License)

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 139
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published: 2026-04-16
Pages: 142
USD 4250.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 120
USD 2900.00 (Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2025
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 90
USD 2900.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-11
Pages: 122
USD 3950.00 (Single User License)